Noninferiority of the PASCAL device relative to MitraClip extends through at least one year, and a substudy finds good outcomes with PASCAL in patients with complex anatomy.
Positive 5-year data argue for early identification and treatment of symptomatic patients in whom transcatheter edge-to-edge repair is appropriate for heart failure with secondary mitral regurgitation.
The new NIH-funded multicenter investigation will help determine which therapy — MitraClip or surgery — is better in which patient types.
Expanded use of minimally invasive mitral valve surgery will be the No. 2 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The COAPT trial finds transcatheter mitral valve repair to be safe and highly effective in a setting with no good treatment options: symptomatic mitral regurgitation secondary to heart failure.
Robotic and catheter-based techniques promise to make mitral valve repair and replacement less invasive than ever. But how effective are they, and are robotic approaches ready to go mainstream?
There’s no end in sight to the past decade of progress in transcatheter aortic valve replacement (TAVR). But experts say the coming years may prove to be the decade of TMVR, or transcatheter mitral valve replacement.
This newly approved percutaneous therapy offers a minimally invasive option for mitral regurgitation patients at high risk from surgery. Ongoing studies aim to better define just which patients benefit.